Actively Recruiting
Identification of Early Markers for ALS
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2025-10-08
60
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
Sponsors
I
Institut National de la Santé Et de la Recherche Médicale, France
Lead Sponsor
T
Technical University of Munich
Collaborating Sponsor
AI-Summary
What this Trial Is About
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies. In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.
CONDITIONS
Official Title
Identification of Early Markers for ALS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 90 years
- Written informed consent provided
- Affiliated with or beneficiary of a social security scheme
- For premotor gene mutation carriers: diagnosed with a disease-causing mutation in a known ALS gene by predictive genetic testing and no other explanation for motor neuron disease symptoms
- For control subjects: no known genetic mutation related to ALS and no known ALS disease in close family, no diagnosed motor neuron disease
- For early ALS or ALS mimics: patients with pure motor symptoms or early ALS symptoms, including those meeting possible ALS criteria or showing only upper or lower motor neuron signs, with symptoms lasting no more than 12 months
You will not qualify if you...
- Unable to provide consent for the study
- Under judicial safeguard, guardianship, or curatorship
- Unable to understand study information due to language or psychological reasons
- Pregnant women
- Unable to attend scheduled visits
- Refusal to provide any required samples (blood, tear fluid, or urine)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Tours
Tours, France, France, 37000
Actively Recruiting
Research Team
P
Philippe CORCIA, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here